Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
about
Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequencesThree agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.Cancer vaccines: the interleukin 2 dosage effectIL2 treatment for cancer: from biology to gene therapyThe effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factorRecurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor.Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.Prevention of hepatic tumor metastases in rats with herpes viral vaccines and gamma-interferon.Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response.Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment.The potential applications of gene transfer in the treatment of patients with cancer: a concise review.Tumor immunotherapy by vaccination with cytokine gene transfected cells.Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour.Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-gamma.
P2860
Q28193430-2C70B74B-1AD0-4700-AC21-58B4E0F2CFE9Q33863928-9B3E1DBC-97CE-49E3-9E9F-B950D533759DQ34361454-0F919485-EA47-4ADA-B6DE-2CBBA3A5CFA0Q35565971-ACCF8190-3A52-4AD7-9E77-FE8D1C8FB37DQ36135662-1DB09C99-4838-44CF-8192-A3B48C6A3231Q36238330-3737BF73-9AC6-4666-A8C9-506975310535Q36366282-067AFD8B-8089-4971-AB9A-423B5F364B5AQ36438502-CC7093CB-8E54-48AF-9A87-099B9171D044Q37340361-99DA1C05-733F-4957-887C-EC95C017DDD3Q37363640-83B7A1EE-44D8-421F-BDE9-DF5707154C55Q40341897-981C912F-80EF-4F17-B8CF-97E80A4A696AQ40603524-253FA3B7-6285-492F-AFD6-0322A9D9370CQ41020855-4938079A-91B5-45C2-BD37-098AA9552F2CQ41455939-712DB244-09D4-49B1-99B3-B9C174DA208EQ41892367-3B8EE937-2DD3-4296-A8D5-79B79D11572CQ41894129-1C6E2958-B971-4BBD-BFDF-5AD03F5C5519Q47864940-C6CC889D-BEC7-4B39-B4DD-CCC2A71E4C8E
P2860
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@en
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@nl
type
label
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@en
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@nl
prefLabel
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@en
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@nl
P2093
P356
P1476
Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo.
@en
P2093
Kourilsky P
Langlade-Demoyen P
Larsson-Sciard EL
P304
P356
10.1002/EJI.1830210350
P407
P577
1991-03-01T00:00:00Z